Zhang Y, Zhang J, Zhou L
Institute of Antibiotics, Hua Shan Hospital Shanghai Medical University.
Zhonghua Nei Ke Za Zhi. 1995 Oct;34(10):676-9.
This study was conducted to evaluate the antibacterial activity of CPZ-SBT in 1,146 clinical isolates and compared with that of CPZ and other antimicrobial agents. CPZ-SBT has much better antibacterial activity than CPZ against B-lactamase producing organisms. Of the 834 gram negative organisms tested, 165 were CPZ resistant, but 94 (57.0%) of them were still susceptible to CPZ-SBT, CPZ-SBT broadens the antibacterial spectrum of CPZ, it has good activity against Acinetobacter spp and B fragilis. Compared with other antimicrobial agents tested, CPZ-SBT is as active as ceftazidime, amikacin and ciprofloxacin against Enterobacteriaceae, P aeruginosa and Acinetobacter spp, but slightly less active than imipenem. It is as active as imipenem, timentin and metronidazole against B fragilis and other anaerobes. The results show that CPZ-SBT is a new member of the broad spectrum antimicrobial agents. It may become a promising agent for the treatment of severe infections caused by cefoperazone-resistant Gram negative bacilli including P aeruginosa.
本研究旨在评估头孢哌酮-舒巴坦（CPZ-SBT）对1146株临床分离菌的抗菌活性，并与头孢哌酮（CPZ）及其他抗菌药物进行比较。CPZ-SBT对产β-内酰胺酶的菌株具有比CPZ更好的抗菌活性。在834株受试革兰阴性菌中，165株对CPZ耐药，但其中94株（57.0%）对CPZ-SBT仍敏感。CPZ-SBT拓宽了CPZ的抗菌谱，对不动杆菌属和脆弱拟杆菌具有良好活性。与其他受试抗菌药物相比，CPZ-SBT对肠杆菌科细菌、铜绿假单胞菌和不动杆菌属的活性与头孢他啶、阿米卡星和环丙沙星相当，但比亚胺培南略低。它对脆弱拟杆菌和其他厌氧菌的活性与亚胺培南、替门汀和甲硝唑相当。结果表明，CPZ-SBT是广谱抗菌药物的新成员。它可能成为治疗由包括铜绿假单胞菌在内的耐头孢哌酮革兰阴性杆菌引起的严重感染的有前景的药物。
